TBPH Stock Slumps 30%, Falls Below 200-DMA For First Time In Over 9 Months As Phase 3 Study Misses Primary Endpoint
The company reported that its Phase 3 CYPRESS study of ampreloxetine in patients with hypotension failed to meet its primary endpoint.
Stocktwits·14d ago
More News
Is Janus Henderson Small Cap Growth Alpha ETF (JSML) a Strong ETF Right Now?
Smart Beta ETF report for JSML
Zacks·18d ago
Should Janus Henderson Small Cap Growth Alpha ETF (JSML) Be on Your Investing Radar?
Style Box ETF report for JSML
Zacks·25d ago
Is Janus Henderson Small Cap Growth Alpha ETF (JSML) a Strong ETF Right Now?
Smart Beta ETF report for JSML
Zacks·3mo ago
Should Janus Henderson Small Cap Growth Alpha ETF (JSML) Be on Your Investing Radar?
Style Box ETF report for JSML
Zacks·3mo ago
Small-Cap Wins in Q3: Top-Performing ETFs in Focus
Small caps staged a comeback in Q3, with ETFs like FESM, RZV, FYX, VTWV, JSML, IWO topping gains. While there are certain tariff risks, the Fed's rate cut potential is a plus.
Zacks·6mo ago
Is Janus Henderson Small Cap Growth Alpha ETF (JSML) a Strong ETF Right Now?
Smart Beta ETF report for JSML
Zacks·7mo ago
Should Janus Henderson Small Cap Growth Alpha ETF (JSML) Be on Your Investing Radar?
Style Box ETF report for JSML
Zacks·7mo ago
BofA: Its 'unlikely small caps will regain their primacy in the next few years'
Investing.com -- Bank of America initiated coverage on 39 small-cap ETFs in a note Thursday, but said it remains cautious on small-caps, arguing that their historical outperformance is unlikely to return anytime soon.